What is HC Wainwright’s Estimate for FHTX FY2025 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a research note issued on Thursday, November 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($1.11) for the year, up from their prior forecast of ($1.15). The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2025 earnings at ($0.27) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.31) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at ($0.08) EPS.

Other equities research analysts also recently issued reports about the company. B. Riley started coverage on Foghorn Therapeutics in a report on Wednesday, September 17th. They set a “buy” rating and a $10.00 price target for the company. Guggenheim started coverage on shares of Foghorn Therapeutics in a research report on Friday. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Wednesday, October 8th. Finally, Wedbush reiterated an “outperform” rating and set a $10.00 price target on shares of Foghorn Therapeutics in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $11.00.

Foghorn Therapeutics Trading Up 9.0%

NASDAQ:FHTX opened at $4.36 on Monday. The firm has a market cap of $246.56 million, a P/E ratio of -3.86 and a beta of 3.02. The stock’s 50 day simple moving average is $4.64 and its 200-day simple moving average is $4.78. Foghorn Therapeutics has a 12-month low of $2.94 and a 12-month high of $9.70.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. The company had revenue of $8.15 million for the quarter, compared to analysts’ expectations of $6.20 million.

Institutional Trading of Foghorn Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Foghorn Therapeutics by 16.1% during the second quarter. JPMorgan Chase & Co. now owns 18,723 shares of the company’s stock worth $88,000 after buying an additional 2,597 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Foghorn Therapeutics by 18.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,908 shares of the company’s stock valued at $84,000 after acquiring an additional 2,812 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Foghorn Therapeutics by 136.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock worth $43,000 after acquiring an additional 5,323 shares in the last quarter. Evelyn Partners Asset Management Ltd acquired a new stake in shares of Foghorn Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Bank of America Corp DE increased its stake in Foghorn Therapeutics by 31.3% in the 2nd quarter. Bank of America Corp DE now owns 31,297 shares of the company’s stock valued at $147,000 after purchasing an additional 7,462 shares in the last quarter. Institutional investors and hedge funds own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.